Author:
Klopp-Schulze Lena,Joerger Markus,Wicha Sebastian G.,ter Heine Rob,Csajka Chantal,Parra-Guillen Zinnia P.,Kloft Charlotte
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference53 articles.
1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–13.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon. International Agency for Research on Cancer. 2013. http://globocan.iarc.fr . Accessed 17 Jan 2017.
3. Institute for Quality and Efficiency in Health Care (IQWiG). Executive summary for final report A10-03: aromatase inhibitors in breast. 2016. https://www.iqwig.de/download/A10-03_Aromatase-inhibitors-in-breast-cancer_Executive-summary-of-final-report_V1-0.pdf . Accessed Mar 2017.
4. Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89:708–17.
5. Maximov PY, Fernandes DJ, McDaniel RE, Myers CB, Curpan RF, Jordan VC. Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells. J Med Chem. 2014;57:4569–83.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献